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EAPP: Gatekeeper at the crossroad of apoptosis and p21-mediated
cell-cycle arrest
P Andorfer and H Rotheneder
Max F. Perutz Laboratories, Department of Medical Biochemistry, Medical University of Vienna, Vienna, Austria
We previously identiﬁed and characterized E2F-asso-
ciated phospho-protein (EAPP), a nuclear phosphoprotein
that interacts with the activating members of the E2F
transcription factor family. EAPP levels are frequently
elevated in transformed human cells. To examine the
biological relevance of EAPP, we studied its properties
in stressed and unstressed cells. Overexpression of EAPP
in U2OS cells increased the fraction of G1 cells and
lead to heightened resistance against DNA damage- or
E2F1-induced apoptosis in a p21-dependent manner.
EAPP itself becomes upregulated in conﬂuent cells and
after DNA damage and stimulates the expression of p21
independently of p53. It binds to the p21 promoter and
seems to be required for the assembly of the transcrip-
tion initiation complex. RNAi-mediated knockdown of
EAPP expression brought about increased sensitivity
towards DNA damage and resulted in apoptosis even in
the absence of stress. Our results indicate that the level
of EAPP is critical for cellular homeostasis. Too much
of it results in G1 arrest and resistance to apoptosis,
which, paradoxically, might favor cellular transformation.
Too little EAPP seems to retard the expression not only
of the p21 gene, but also of a number of other genes and
ultimately results in apoptosis.
Oncogene (2011) 30, 2679–2690; doi:10.1038/onc.2010.639;
published online 24 January 2011
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Introduction
The cell cycle of all eukaryotes is controlled by cyclin-
dependent kinases (CDKs), the catalytic partners of
cyclins (Sherr and Roberts, 2004). A variety of
checkpoint mechanisms have evolved that monitor
cell-cycle progression and respond to perturbations
like replication errors or DNA damage by modifying
the activity of CDKs (Hartwell and Weinert, 1989;
Pietenpol and Stewart, 2002). Cyclin-dependent kinase
inhibitors interact with CDKs and inhibit their activity
(Chen et al., 1996). The tumor suppressor p53 is a com-
ponent of several checkpoints (Giono and Manfredi,
2006) and controls the expression of various growth-
inhibitory or apoptotic genes (Rozan and El-Deiry,
2007). Among these is the CDKN1A gene that codes for
p21 (or p21
WAF1/Cip1), which induces growth arrest by
binding and inhibiting CDK complexes (el-Deiry et al.,
1993; Chen et al., 1995; Goubin and Ducommun, 1995)
and by sequestering away proliferating cell nuclear
antigen from DNA polymerase d (Flores-Rozas et al.,
1994; Waga et al., 1994). Thereby, but also by its ability
to promote cellular senescence and differentiation,
p21 prevents the development of tumors (for reviews
see (Abbas and Dutta, 2009; Cazzalini et al., 2010).
In addition, p21 inﬂuences gene expression via certain
promoter elements (Zhu et al., 2002) and by its inter-
action with transcription factors (Delavaine and La
Thangue, 1999; Kitaura et al., 2000). Paradoxically, p21
also prevents apoptosis (Roninson, 2002) on the one
hand because the initiation of apoptosis often requires
an active cell cycle, on the other hand by interference
with apoptotic signaling (Asada et al., 1999) and caspase
activation (Suzuki et al., 1999; Baptiste-Okoh et al., 2008)
Some of these antiapoptotic activities depend on the
cytoplasmic localization of p21 (Blagosklonny, 2002).
We have previously identiﬁed and characterized an
E2F-binding protein, which we termed E2F-associated
phospho-protein (EAPP) (Novy et al., 2005) and which
we found overexpressed in many tumor cell lines. EAPP
interacts with E2F1-3, comprising the activator group of
E2F proteins, and modulates E2F-dependent transcrip-
tion. Its expression is regulated by the transcription
factors Sp1, Sp3 and Egr-1 binding to the TATA-less
promoter of the EAPP gene (Schwarzmayr et al., 2008).
Very recently it has been shown that EAPP negatively
regulates the expression of monoaminoxidase B via Sp1
binding sites (Chen et al., 2010).
We show in this study that EAPP levels increase upon
DNA damage and higher EAPP levels seem to protect
cells from apoptosis. This protection can also be
achieved by ectopic expression of EAPP and correlates
with an increased number of cells in G1 phase and an
upregulation of p21. RNAi-mediated knockdown of p21
abrogates this effect of EAPP. Knockdown of EAPP on
the other hand results in apoptosis. We analyzed the
expression of p21 by western, reverse transcription–PCR
(RT–PCR) and reporter gene assays and could show
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www.nature.com/oncthat the knockdown of EAPP reduces p21 mRNA and
protein, whereas overexpression of EAPP results in
elevated p21 levels. Chromatin immunoprecipitation
(ChIP) experiments demonstrated that EAPP binds to
the p21 promoter in the vicinity of the TATA box and
might be involved in transcription initiation.
Results
Overexpression of EAPP alters cell-cycle progression
We have shown earlier that EAPP can inﬂuence the cell
cycle and many transformed cell lines exhibit elevated
levels of EAPP (Novy et al., 2005). To examine whether
EAPP is involved in the response to stress, we compared
the effects of certain drugs known to inhibit cell-cycle
progression in cells with different EAPP levels. We
transfected U2OS cells with either an expression vector
for EAPP or an empty vector and treated these cells
with nocodazole and colchicine that arrest cells in
mitosis by interfering with the assembly of the mitotic
spindle, or with etoposide and methyl-methanesulfo-
nate, which cause DNA damage and cell-cycle arrest,
preferentially in S or G2 phase. Subsequently the
cells were analyzed by ﬂow cytometry. In all four cases
the ectopic expression of EAPP brought about a
prominent G1 peak not present in mock-transfected
cells (Figure 1a). As it is very improbable that EAPP
can overcome the effects of four different drugs, the
most likely explanation seemed to be an EAPP-induced
slowing-down of the cell cycle resulting in an accumula-
tion of cells in G1. Gating of U2OS cells expressing a
green ﬂuorescent protein (GFP)-tagged version of EAPP
revealed that the cells that expressed GFP-EAPP had a
higher G1 fraction than those that did not (Figure 1b).
The EAPP-induced G1 arrest is mediated by p21
Cells approaching conﬂuency usually grow slower and
this is at least partially caused by elevated p21 (Perucca
et al., 2009). As overexpression of EAPP resulted in
slower growth, we checked whether EAPP also goes up
with increasing cell density. Figure 2a shows that this
is indeed the case, suggesting a possible connection
between the two proteins. To examine this we expres-
sed either GFP or GFP-EAPP with or without a
p21-speciﬁc small interfering RNA in U2OS cells
(Figure 2b). The GFP-positive cells were then analyzed
by ﬂow cytometry to determine and compare the frac-
tion of cells in G1-, S- or G2-phase (Figures 2c and d).
The comparison of GFP-positive and GFP-negative
cells on the one hand and of GFP- and GFP-EAPP-
expressing cells on the other hand demonstrated again
the cell cycle slowing property of EAPP. The knock-
down of p21 abrogated this growth-retarding effect,
suggesting that it is exclusively or at least primarily
mediated by p21.
EAPP regulates p21 expression via Sp1 sites and binds to
the p21 promoter
Western analysis showed that increasing the level of
EAPP results in higher p21, whereas a knockdown of
EAPP lowers p21 (Figure 3a). To ﬁnd out whether
EAPP inﬂuences the expression or the stability of p21,
we ﬁrst performed RT–PCR and compared the p21
mRNA levels in cells with lowered, normal and elevated
EAPP. Figure 3b shows that knockingdown EAPP
resulted in a concomitant reduction of p21 mRNA,
whereas overexpression of EAPP caused a modest rise
of p21 mRNA. To determine whether EAPP inﬂuences
p21 mRNA levels by affecting promoter activity, we
carried out reporter assays. It turned out that the
knockdown of EAPP reduced promoter activity,
whereas its ectopic expression stimulated the promoter
(Figure 3c). Conversely, the cyclin A promoter was not
inhibited by the knockdown of EAPP but even slightly
stimulated (Supplementary Figure 2). A major determi-
nant for the transcription rate of a protein-coding gene
is its occupancy by RNA polymerase II (Pol II).
To examine whether EAPP can inﬂuence the activity
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Figure 1 EAPP overexpression increases the G1 fraction of U2OS cells. (a) U2OS cells were transfected with an expression vector for
HA-EAPP or a control vector and treated with different drugs for 16h. Nocodazole and colchicine arrest cells during mitosis,
etoposide and methyl-methanesulfonate cause DNA damage, hence stall cells in S-phase. Harvested cells were analyzed for cell-cycle
distribution. (b) To investigate untreated cells either a GFP-EAPP or a GFP control vector were transfected into U2OS cells, gated for
their GFP levels and separately analyzed.
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Oncogeneof Pol II on the p21 gene, we performed ChIP with an
anti-Pol II antibody. These experiments demonstrated that
the presence of Pol II on the exon 1 of the p21 gene is
severely reduced upon knockdown of EAPP (Figure 3d).
To determine the sequence requirements for the observed
effects, we carried out luciferase assays with the full-length
p21 promoter and several truncations thereof (Figure 3e)
and compared their activity under normal and EAPP
knockdown conditions. The proximal promoter compris-
ing four of the six Sp1 (nucleotides  101 to þ16 relative
to the transcription start site) is sufﬁcient to confer
regulation by EAPP (Figure 3f). Mutation of either one
of the two distal of these sites (Sp1 binding sites 3 and 4)
abolished the inﬂuence of EAPP (Figure 3g).
To ﬁgure out whether EAPP is associated with the
p21 promoter, we conducted ChIP assays and ampliﬁed
precipitated DNA from ﬁve different regions of the p21
gene (Figure 4a). Appreciable precipitation with an anti-
EAPP antibody could only be achieved with the region
comprising the TATA box (Figure 4b).
EAPP seems to inﬂuence the assembly of the preinitiation
complex
Histone modiﬁcation is one of the key mechanisms in
transcriptional regulation. The protruding N-terminal
domains of histones are subject to methylation, acetylation
and phosphorylation (Li et al., 2007b). We performed ChIP
assays with modiﬁcation-speciﬁc anti-histone antibodies
to investigate whether EAPP alters the histone modiﬁ-
cation status of the promoter and thereby inﬂuences p21
transcription. Neither the general acetylation of H3 and
H4, nor the speciﬁc K9 acetylation on H3, nor the
phosphorylation of S10 on H3 showed any alteration upon
EAPP knockdown (Supplementary Figure 3). The binding
of p53 to its cognate binding sites further upstream on
the p21 promoter also remained unchanged (Figure 4c).
Interestingly, a fraction of p53 can also be found at the
TATA region. It might represent Sp1-associated p53
(Lagger et al., 2003) and/or might be brought to the TATA
box by looping of the DNA (Li et al., 2007a). This fraction
of p53 was reduced upon EAPP depletion (Figure 4c).
Binding of TBP at the TATA box and bending of the
DNA is considered the ﬁrst step in the assembly of the
preinitiation complex on TATA box containing promoters.
This is followed by the recruitment of TAFs (TBP
associated factors) to constitute TFIID, the binding of the
other components of the basal transcription machinery and
ﬁnally the association with RNA pol II (reviewed in
(Kornberg, 2007; Sikorski and Buratowski, 2009)). To
examine whether reducing EAPP interferes with the build
up of the transcription initiation complex, we again carried
out ChIP assays in EAPP knockdown and control cells.
Reduction of EAPP did not inﬂuence the binding of TBP
but the presence of TAF 1 and TAF 4, Pol II and cdk 9 was
clearly reduced in these cells. In contrast, the binding of
transcription factors was either not affected (E2F1) or even
increased (Sp1) by lower EAPP levels (Figures 4c, d and e).
EAPP is involved in the DNA damage-induced
upregulation of p21
DNA damage results in the induction of p53, which
in turn stimulates the expression of p21. We used
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Figure 2 p21 has a major role in the EAPP-triggered G1 cell-cycle arrest. Its knockdown abrogates the growth-inhibiting effect of
EAPP. (a) Rising cell density results in higher EAPP and p21 levels as shown on a western blot (upper panel) and increases the
fraction of G1 cells as shown by FACS analysis (lower panel). (b) U2OS cells were transfected with expression vectors for GFP
or GFP-EAPP with or without an expression vector for small hairpin RNA targeting p21 mRNA and analyzed by western blotting and
immunostaining with an anti-p21 antibody. (c) The same cells were gated for GFP expression and separately analyzed by ﬂow
cytometry. (d) The cell-cycle distribution of GFP-positive cells of three independent experiments were quantiﬁed with FlowJo
(Tree Star Inc, Ashland, OR, USA) and averaged. All data are presented as the mean±s.d. from at least three independent
experiments. *Po0.05.
EAPP: At the crossroad of apoptosis and arrest
P Andorfer and H Rotheneder
2681
Oncogenep53-positive U2OS cells to ﬁnd out whether EAPP is
not only required for basal expression, but also takes
part in the stress-induced activation of p21. DNA
damage was induced with etoposide and p21 mRNA
expression was examined with lowered, normal and
elevated EAPP levels (Figure 5). Overexpression of
EAPP not only increased p21 mRNA in control cells,
but also in etoposide-treated cells with already elevated
p21 mRNA (Figure 5a). In p53 negative T98G cells,
the overall level of p21 mRNA was much lower but
still stimulated by EAPP, indicating that this effect is
p53-independent (Figure 5b). To follow the induction of
EAPP by etoposide more closely, time-course experi-
ments were performed. Figure 5c shows the level of p21
mRNA and EAPP between 0 and 9h after etoposide
addition. Their parallel increase in both, normal and
EAPP knockdown cells indicates that besides p53,
DNA damage-induced EAPP might also contribute to
the upregulation of the p21 promoter. Protein levels of
p21 also increased and decreased with EAPP in normal
and etoposide-treated cells. DNA damage-induced p53
was not affected by changes in EAPP levels. Inhibition
of histone deacetylase (HDAC) activity by TSA also
resulted in elevated p21 and EAPP levels. The knock-
down of EAPP lowered p21 also in the presence of TSA,
conﬁrming that this effect is not acetylation dependent
(Supplementary Figure 4).
EAPP has antiapoptotic properties that depend on p21
In EAPP overexpressing cells, the fraction of apoptotic
cells following etoposide addition was clearly reduced
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Figure 3 EAPP regulates p21 at the level of transcription via Sp1 binding sites. (a) Western blot showing a p21 decrease after knock
down of EAPP and an increase upon EAPP overexpression. b-Actin served as a loading control (b) RT–PCR of p21 mRNA after
EAPP knockdown and overexpression. (c) Reporter assay with the full-length p21 promoter. Knockdown of EAPP decreases the
Luciferase activity, whereas overexpression results in an increase. (d) ChIP showing exon 1 associated RNA pol II in EAPP
knockdown and control cells. The lower panel depicts the actual data, the upper panel the quantiﬁcation. pSuper-Scrambled is the
RNAi control vector for the expression of an unspeciﬁc small hairpin RNA. (e) Schematic illustration of the used p21 luciferase
constructs. (f, g) Luciferase assays with p21 promoter constructs under normal and EAPP knockdown conditions. A luciferase activity
of 1 was assigned to the p21-wt promoter in f and to the p21-101 promoter in g. The lower panels are western blots showing the
respective EAPP levels with GAPDH as a loading control. All data are presented as the mean±s.d. from at least three independent
experiments. *Po0.05; **Po0.01.
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Oncogene(Figure 6a). Quantiﬁcation showed a signiﬁcant smaller
fraction of apoptotic cells in EAPP overexpressing cells
even after prolonged exposure to etoposide (Figure 6b).
The same result was obtained by analyzing the apop-
totic fraction in the forward/side scatter plot in ﬂow-
cytometric analysis. Apoptotic cells have lower forward
scatter and slightly higher side-scatter values and appear
as a distinguishable population (not shown). Apoptosis
can also be induced by overexpression of E2F1
(Qin et al., 1994; Shan and Lee, 1994; Wu and Levine,
1994) in p53-dependent and -independent manners
(Phillips and Vousden, 2001), which again was pre-
vented by the simultaneous expression of EAPP (Figures
6c and d). If apoptosis can be inhibited by EAPP
overexpression, conversely its knockdown should
facilitate apoptosis. To test this hypothesis, EAPP levels
in U2OS and T98G cells were lowered by RNAi. To
make sure that the observed cell death results from
apoptosis, we stained the cells with YoPro-1 (Idziorek
et al., 1995), which allowed the selection of apoptotic
and dead cells and with propidium iodide (PI) that
allowed the discrimination between early apoptotic and
late apoptotic plus dead cells. In addition, we performed
western analysis and looked for cleaved caspase 3, a
hallmark of apoptosis. The number of cells with a sub-
G1 DNA content and the amount of cleaved caspase 3
increased dramatically in both, p53-positive U2OS
(Figure 7a) and p53-negative T98G cells (Figure 7b)
with lowered EAPP, indicating that this effect is p53
independent.
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Figure 4 EAPP binds around the TATA box of the p21 promoter and inﬂuences the binding or assembly of the basal transcription
machinery and Sp1. (a) Schematic drawing of the p21 promoter region depicting the regions that were ampliﬁed after ChIP to
characterize EAPP binding. (b) ChIP experiments in U2OS cells showed that EAPP could only be found in the region ampliﬁed by the
TATA box primer pair. The lower panel shows a representative experiment, the upper panel the quantiﬁcation. (c) ChIP assays with
p53- and Pol II-speciﬁc antibodies probing the p53-binding sites and the TATA box region. (d, e) ChIP assays with TAF1-, TAF4-,
Pol II-, CDK9-, E2F1- and Sp1-speciﬁc antibodies of the TATA and control regions. All data are presented as the mean±s.d. from
at least three independent experiments. *Po0.05; **Po0.01.
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OncogeneTo further investigate the requirement for EAPP, we
examined U2OS cells and U2OS cells with moderately
lowered EAPP levels under normal and DNA damage
conditions. Equal numbers of these cells were seeded either
in normal growth medium or in growth medium with
low concentrations of etoposide and counted for 4 days.
Whereas the number of cells in plain growth medium
steadily increased with little difference between normal and
EAPP knockdown cells, the number of etoposide-treated
c e l l sd e c r e a s e da f t e ra ni n i t i a lr i s e .T h i sd e c r e a s ew a sm u c h
more pronounced in the EAPP knockdown cells again
emphasizing the protective role of EAPP (Figure 8a). This
goes along with a reduced induction of p21 (Figure 8b)
and a much higher degree of apoptosis in EAPP knock-
down cells. Staining with YoPro-1 and PI and subsequent
ﬂow-cytometric analysis allowed the quantiﬁcation of this
difference (Figures 8c and d).
To examine whether the antiapoptotic activity of EAPP
is also mediated by p21, we determined the fraction of
apoptotic cells at 24, 48 and 72h after the induction of
DNA double-strand breaks in control cells, cells with
elevated EAPP, cells with lowered p21 and cells with both,
elevated EAPP and lowered p21. It turned out that the
antiapoptotic activity of EAPP is greatly diminished by the
knockdown of p21 (Figure 9). This indicates that this
activity of EAPP is indeed mainly mediated by p21 but
other factors might also be involved.
Discussion
Following DNA damage, a cell of a multicellular
organism can repair the damage, withdraw from the
cell cycle and enter senescence, or eliminate itself by
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Oncogeneapoptosis to avoid the proliferation of aberrant descen-
dants, possibly resulting in cancer. Among the main
players in this process are the tumor suppressor p53 and
its transcriptional target p21. Treatment of cancer cells
with certain drugs often induces p21 followed by cell-
cycle arrest and/or cellular senescence and this can
protect cells from drug-induced apoptosis (Kawasaki
et al., 1996; Waldman et al., 1996; Gartel and Tyner,
2002). p21 seems to accomplish this either by inhibiting
CDK activity (Chen et al., 1996) or by modulating the
activity of transcription factors or apoptosis regulators
(Janicke et al., 2007).
EAPP is an evolutionary conserved phosphoprotein
with a predominant nuclear localization that is freq-
uently upregulated in transformed cells. We have pre-
viously identiﬁed it as an E2F-binding protein that
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Oncogenemodulates the activity of E2F-dependent promoters
(Novy et al., 2005).
In our current study, we analyzed the role of EAPP
under DNA damage conditions and examined the
impact of its overexpression and knockdown. The
treatment with drugs that interfered with cell-cycle
progression by activating cellular checkpoints revealed
that the fraction of G1 cells was much higher in EAPP-
overexpressing than normal U2OS cells (Figure 1).
This indicates that more EAPP either slowed down the
cell cycle or even arrested these cells in G1, or that
EAPP somehow abolished the effects of the drugs. The
only plausible mechanism for blocking the drugs seemed
to be the activation of multidrug resistance (MDR)
genes, encoding large transmembrane transporters
able to remove toxic substances from a cell (Gutmann
et al., 2010). To examine this possibility we compared
the levels of several MDR proteins in normal EAPP
overexpressing cells. We indeed detected a stimulating
effect on the expression of P-glycoprotein (Gros et al.,
1986; Goda et al., 2009), but the measurement of the
efﬂux of a dye revealed that the drug-transport activity
of EAPP overexpressing cells was not increased and
could thus not explain our observations (not shown).
Transfection with either a GFP or a GFP-EAPP expres-
sion vector and the separate assessment of transfection-
positive and transfection-negative cells conﬁrmed that
EAPP overexpression results in G1 arrest. Earlier ﬁnd-
ings that EAPP stimulates cell-cycle progression (Novy
et al., 2005) might be explained by a differing methodo-
logy. At that time we were not able to separately analyze
transfected and untransfected cells.
The growth-inhibitory activity of EAPP turned out to
be p21-dependent as it was abrogated by the knockdown
of p21. In line with this ﬁnding, p21 protein and mRNA
levels, as well as its promoter activity, went up with
increasing, and down with lowered EAPP levels showing
that EAPP inﬂuences the expression of p21. This, and
the observation that U2OS cells approaching conﬂuency
increase both, their EAPP and p21, but not p53 levels
suggested that EAPP is among the driving forces behind
the increase of p21 in conﬂuent cells (Figure 2).
Furthermore, a knockdown of EAPP inhibits this cell
density-dependent increase of p21 (Figure 8b).
The p21 promoter shows a complex pattern of
regulation and a variety of DNA-binding factors, as
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Oncogenewell as chromatin remodeling and histone-modifying
complexes determine its activity (reviewed in (Gartel
and Radhakrishnan, 2005; Abbas and Dutta, 2009)).
The observed modulation of p21 promoter activity by
EAPP could occur either by direct binding to DNA, by
affecting other promoter-binding factors, or chromatin-
modifying processes. ChIP assays demonstrated that
EAPP associates with the region around the TATA box
(Figure 4). The histone modiﬁcation pattern in the
vicinity of the TATA box was not affected by differing
EAPP concentrations and thus does not seem to be
involved (Supplementary Figure 3).
Whereas elevating or lowering EAPP had no impact
on the binding of E2F1 and TBP, there was a clear
reduction of promoter-bound TAF 1, TAF 4, Pol II and
cdk9 (Figure 5b,c and d). EAPP might thus be required
for the efﬁcient assembly of the pre-initiation complex at
the p21 promoter. Reduced binding of cdk9, which is
required for elongation (Peng et al., 1998), might just be
a consequence of inefﬁcient initiation or it might itself
require EAPP for promoter association. Binding of Sp1
on the other hand was elevated upon EAPP knock down
(Figure 4e). This is in line with a very recent report
(Chen et al., 2010) showing that EAPP can directly bind
to DNA and compete with Sp1 for its binding site.
Moreover, two of the six Sp1 binding sites seem to
mediate the activity of EAPP on the p21 promoter as
their mutation abolished any effect of an EAPP knock-
down (Figures 3e and g). This could mean that the
putative role of EAPP in transcription initiation is more
important for p21 promoter activity than binding of Sp1
to these sites.
p21 expression is strongly stimulated following DNA
damage. This is primarily caused by damage-induced
p53 but can also be seen to a lesser degree in p53
negative cells. The increase of EAPP under damage
conditions suggested that it contributes to the p21
induction. This is also supported by the observation that
the knockdown of EAPP severely hampers the p21
induction after DNA damage or HDAC inhibition
(Figure 5; Supplementary Figure 4).
The observed increase of EAPP in many transformed
cell lines (Novy et al., 2005) suggested that these cells
beneﬁt from higher EAPP levels despite the concomitant
stimulation of growth-retarding p21. Inhibition of
apoptosis seemed to be a likely mechanism. And indeed,
overexpression of EAPP impeded DNA damage but
also E2F1-induced apoptosis (Figure 6), whereas its
knockdown resulted in apoptosis even without damage.
As this apoptosis also occurred in p53-negative T98G
cells, it is at least not absolutely dependent on p53
(Figure 7). The antiapoptotic activity of EAPP is
also mediated mainly by p21 as it almost completely
abolished by a concurrent knockdown of p21 (Figure 9).
To ﬁnd out whether a modest reduction of EAPP levels
can also make a difference under stress conditions, we
treated cells with low amounts of etoposide, which
perhaps comes closer to naturally occurring events a cell
can encounter. Then we compared cells with normal and
moderately lowered EAPP content. This revealed that a
modest reduction, which only slightly impairs cell
proliferation under normal growth conditions, drasti-
cally lowered their viability following DNA damage
(Figure 8).
Taken together our ﬁndings suggest that EAPP is
indispensable for the survival of a cell. The required
amount of EAPP seems to depend on the environmental
conditions. Under optimal conditions for cell growth
less is needed, whereas stress seems to favor cells
expressing more EAPP (Figure 9c). This might also be
an explanation for the high EAPP levels observed in
many transformed cells. The CDK inhibitor p21 seems
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Oncogeneto have an important role as a mediator of the anti-
apoptotic activity of EAPP. In the absence of sufﬁcient
EAPP, the assembly of the transcription initiation
complex at the p21 promoter seems to be perturbed.
Depending on the extent of the reduction of EAPP, p21
is downregulated or just not upregulated, and under
stress conditions cannot carry out its cell-protecting
functions. Most likely other proteins beside p21 are also
involved in apoptosis caused by the loss of EAPP, as in
unperturbed growing cells a p21 knockout has no severe
effect (Deng et al., 1995). Preliminary evidence suggests
that the role of EAPP in transcription is not limited to
the p21 promoter. Active promoters are occupied by
multiple types of complexes (Sikorski and Buratowski,
2009) and EAPP seems to be an important compo-
nent of at least some of them. Lowering EAPP levels
inﬂuenced the expression of some of the genes examined
(unpublished results). Among them are genes enco-
ding important cell-cycle regulators like proliferating
cell nuclear antigen, cyclin B, cdk1 and p27 the level of
which went down with EAPP. To examine which genes
are inﬂuenced by EAPP and to scrutinize the bio-
chemical details of its activity will be focus of future
experiments.
Materials and methods
Plasmids, reporter constructs and reagents.
pCIneo-HA-EAPP, pEGFP-C, pEGFP-EAPP, pGAL-Luc,
pSuper-EAPP-#2 (Novy et al., 2005), p21-Luc and mutations
thereof (Sowa et al., 1997), pSuper-p21 (Karakas et al., 2007),
pSuper-SCR (Rayter et al., 2008) and pCIneo-HA-DP1(Helin
et al., 1993) have been described. For the pGFP-E2F1 the E2F1
complementary DNA (cDNA) was recloned from the pGex2T-
E2F1 (Rotheneder et al., 1999) into the pEGFP-C vector.
The pSuper-EAPP-#1 and #3 were generated by cloning a double
stranded oligonucleotide with the sequences 50-AAGTTGCAA
CAGCTCCGAC-30 for #1 and 50-GATTCCAACAAATGACG
AA-30 for #3 of the EAPP cDNA as an inverted repeat into the
pSuper vector. The impact of individual and combined transfec-
tion of pSuper-EAPP-#1, #2 and #3 is shown in Supplementary
Figure 1. Etoposide, nocodazole, methyl-methanesulfonate and
colchicine were purchased from Sigma (Taufkirchen, Germany).
Cell culture and transfection
U2OS and T98G cells were cultured in DMEM containing
10% (vol/vol) fetal calf serum. Cells were transfected for 16h
using PerFectin (Genlantis, San Diego, CA, USA). Following
a change of the medium, the cells were grown for addi-
tional 24–48h. As control vector for mock transfec-
tions we used either pEGFP-C (Clontech, Mountain View,
CA, USA) for the expression of GFP, pSuper-Scrambled for
the expression of an unspeciﬁc small interfering RNA, or an
empty pCI-neo vector (Clontech).
Western blot analysis, antibodies, RNA isolation
and RT–PCR
Whole-cell extracts were prepared by lysing the cells using a
lysis buffer (20mM Tris pH8, 100mM NaCl, 1mM EDTA,
0.5% NP-40). The separation was performed by 8–14%
sodium dodecyl sulfate–PAGE. Proteins were then transferred
onto nitrocellulose membranes and probed with indicated
antibodies, followed by enhanced chemiluminescence detec-
tion. RNA isolation was done with the TRIzol Reagent from
Invitrogen (Carlsbad, CA, USA), following the recommended
protocol. The cDNA was prepared with the Revert Aid First
Strand cDNA Synthesis Kit from Fermentas (Burlington,
Canada) and PCR was performed with a Maxima Hot Start
Green PCS Master Mix from Fermentas.
Luciferase reporter assay
Luciferase reporter assays were carried out as previously
described (Novy et al., 2005) with full-length or truncated
p21 promoter-luciferase reporter constructs (Sowa et al.,
1997). b-Galactosidase activity was assayed in parallel as a
control for the transfection efﬁciency (Novy et al., 2005).
Chromatin immunoprecipitation assays
ChIP’s were carried out as previously described (Hauser et al.,
2002). Following Antibodies were used: Pol II (N-20), TAF1
(6B3), TAF4 (4A6), TBP (SI-1), CDK9 (H-169), SP1 (PEP-2)
and E2F1 (KH95) from Santa Cruz Biotechnology (Santa Cruz,
CA, USA), H3 (1791) from Abcam (Cambridge, UK), H3ac (06-
599), H4ac (06-866), S10Ph (05-598) and K9ac (06-942) from
Upstate (Millipore, Billerica, MA, USA) and the EAPP anti-
body. Input was used in a 1/30 dilution and PCRs were
performed with a Maxima Hot Start Green PCS Master Mix
(Fermentas, St. Leon-Rot, Germany) and products were resolved
on a 2% agarose gel. ImageQuant 5.2 (Molecular Dynamics,
Krefeld, Germany) was used to quantify three independent
experiments in comparison with the input.
Cell-cycle analysis
The cell-cycle distribution was measured with DAPI (Merck,
Darmstadt, Germany, Figure 1a), PI (Sigma, Figures 2a, 7a, b
and 8c), Hoechst 33258 (Invitrogen, Figures 1b, 2c, and 6a), or
Draq5 (Biostatus Limited, Leicestershire, UK; Figure 6c).
Cells were trypsinized, washed once with phosphate-buffered
saline and around 5 10
5 cells were taken for analysis. For
Hoechst 33258 and Draq5, which stain viable cells, appro-
priate concentrations of the dyes were used and incubated for
20min on 41C in the dark (Draq5 10mM, Hoechst 33258 5mg/
ml). For DAPI and PI cells were ﬁxed in 85% ethanol and
incubated at least 30min on ice. PI was used in a ﬁnal
concentration of 50mg/ml and 100mg/ml RNAse Typ 1-A was
added and incubated for 30min at room temperature in the
dark. DAPI concentration was 2ng/ml and ﬁxed cells were
incubated for 20min in the dark at 41C. To analyze the cell-
cycle distribution different devices were used. DAPI staining
was measured with a Pas-III from Partec (Muenster, Ger-
many), PI and Draq5 with a FACS-Calibur (BD Bioscience,
San Jose, CA, USA), and Hoechst 33258 with a FACS-Aria
(BD Bioscience). Hoechst 33258 and Draq5 allowed an
additional staining with and gating for GFP. With the
FACS-Calibur and FACS-Aria cell debris and doublets were
excluded.
Apoptosis and cell count
Cells were counted with a CASY Cell Counter TTC (Scha ¨ rfe
System, Reutlingen, Germany). To detect apoptosis different
assays were carried out. For all procedures cells were
trypsinized, washed once with phosphate-buffered saline and
around 5 10
5 cells were taken for measurement. The same
procedure as described in the cell cycle analysis part was
applied for sub-G1 analysis. Beforehand a threshold was set to
discriminate against the cell debris. For the Vybrant Apoptosis
Assay Kit (Invitrogen) cells were stained with PI and YO-PRO
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Oncogeneaccording to the protocol from Invitrogen. YO-PRO
enters only into early apoptotic cells, whereas PI stains all
permeabilized cells. Again a threshold was set to exclude cell
debris. Necrotic cells have either a higher forward scatter
signal due to cell swelling or disappear in the cell debris upon
bursting. In contrast, apoptotic cells have a smaller forward
scatter signal before they give origin to many small apoptotic
bodies, which generally end up as debris. YO-PRO-positive
cells with a smaller forward scatter were gated and separated
into PI-positive cells (late apoptosis or already dead cells)
and PI-negative cells (early apoptosis). Hoechst 33258 brightly
stains the condensed chromatin of apoptotic cells, hence,
the ﬂuorescence intensity increases. A threshold excluding
the cell debris was set and GFP-positive cells were gated
and percentage of cells with higher Hoechst 33258 values
and smaller forward scatter values were measured. All ﬂow-
cytometry experiments were done with a FACS-Calibur or a
FACS-Aria from BB Bioscience.
Data analysis
Data in all experiments are represented as mean±s.d.
Statistical analysis was carried out using unpaired t-test. The
P-values of o0.05 were considered to be statistically sig-
niﬁcant. *Po0.05; **Po0.01.
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